Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Safinamide in Parkinson's Disease
NCT00865579Phase 3Terminated
- Sponsor
- Newron Pharmaceuticals
- Start
- Apr 2009
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of safinamide in Parkinson's disease (PD), sponsored by Newron Pharmaceuticals. Started Apr 2009; status: terminated.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00865579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00865579.